Cargando…
More Unnecessary Imaginary Worlds - Part 1: The Institute for Clinical and Economic Review’s Evidence Report on Janus Kinase (JAK) Inhibitors in Rheumatoid Arthritis
Previous commentaries in the Formulary Evaluation section of INNOVATIONS in Pharmacy have pointed to the lack of credibility in modeled claims for cost-effectiveness and associated recommendations for pricing by the Institute for Clinical and Economic Review (ICER). The principal objection to ICER r...
Autor principal: | Langley, Paul C |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
University of Minnesota Libraries Publishing
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8132526/ https://www.ncbi.nlm.nih.gov/pubmed/34017631 http://dx.doi.org/10.24926/iip.v11i1.2402 |
Ejemplares similares
-
More Unnecessary Imaginary Worlds – Part 3: Cystic Fibrosis and the Institute for Clinical and Economic Review’s Draft Evidence Report
por: Langley, Paul C
Publicado: (2020) -
More Unnecessary Imaginary Worlds – Part 2: The ICER Evidence Report on Modeling Oral Semaglutide for Type 2 Diabetes
por: Langley, Paul C
Publicado: (2020) -
More Unnecessary Imaginary Worlds – Part 4: The ICER Evidence Report for Crizanlizumab, Voxelotor and L-Glutamine for Sickle Cell Disease
por: Langley, Paul C
Publicado: (2020) -
CVS Health and the Imaginary Worlds of the Institute for Clinical and Economic Review (ICER)
por: Langley, Paul C
Publicado: (2018) -
Supping with the Devil: Belief and the Imaginary World of Multiple Myeloma Therapies Invented by the Institute for Clinical and Economic Review
por: Langley, Paul C
Publicado: (2021)